Group 1: Company Overview and Competitive Advantages - The company has a strong brand and operational team that supports rapid growth in e-commerce, covering major platforms like Alibaba Health, JD Pharmacy, and Douyin [2] - The e-commerce business has achieved approximately 50% annual growth over the past five years, with 2023 revenue reaching 172 million CNY, accounting for 21.88% of total revenue [2] Group 2: Product Development and Market Strategy - The first batch of products from Henan Xinxin, including antiviral and detoxification oral liquids, has been launched, with sales meeting company expectations and several million CNY in orders already placed [3] - Production of Henan Xinxin products is outsourced to various manufacturers to leverage local advantages, with specific responsibilities assigned to different facilities [3] Group 3: Financial Health and Shareholder Returns - The company maintains a healthy cash flow and adheres to a stable dividend policy, having executed its post-listing dividend plan since inception [3] - The company is responsive to regulatory calls for active dividend distribution, aiming to share growth results with shareholders [3]
恩威医药(301331) - 301331恩威医药投资者关系管理信息20250109